Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420855 | 0.86 | KDM4E (0.30) | — | |
| SCHEMBL724276 | 0.80 | — | — | |
| SCHEMBL11979591 | 0.80 | KDM4E (0.35) | DHFRTSHRSMN1; SMN2TDP1HPGD | |
| SCHEMBL7987882 | 0.78 | HPGD (0.35) | DHFRTSHRSMN1; SMN2TDP1HPGD | |
| SCHEMBL10396368 | 0.76 | DHFR (0.31) | DHFRTSHRSMN1; SMN2TDP1HPGD | |
| SCHEMBL11244693 | 0.76 | HPGD (0.34) | DHFRTSHRSMN1; SMN2TDP1HPGD | |
| SCHEMBL17188793 | 0.74 | ALDH1A1 (0.37) | SMN1; SMN2HPGD | |
| SCHEMBL15625528 | 0.74 | KDM4E (0.46) | TSHR | |
| SCHEMBL4719324 | 0.74 | — | — | |
| SCHEMBL13113281 | 0.73 | FAAH (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | claimed |
| EP-2997028-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-03-23 | — | — | EP | claimed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | claimed |
| WO-2014184163-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | claimed |
| US-4891305-A | LASERS | RICOH CO., LTD. (JP) | 1990-01-02 | — | — | US | claimed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2997028-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014184163-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-4891305-A | LASERS | RICOH CO., LTD. (JP) | 1990-01-02 | — | — | US | disclosed |
| US-4863832-A | Optical recording employing diacetylene compound and dye to change color and form pits | CANON KABUSHIKI KAISHA (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0295144-A1 | Optical recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-12-14 | — | — | EP | disclosed |
| US-4782006-A | IRRADIATION POLYMERIZATION | CANON KABUSHIKI KAISHA (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0278763-A2 | Information recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-08-17 | — | — | EP | disclosed |
| EP-0264274-A2 | Optical recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0264198-A2 | Optical information recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4555472-A | OPTICAL RECORDING MEDIA | CANON KABUSHIKI KAISHA (JP) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | DHFR 1274/4885TSHR 1187/4885SMN1; SMN2 1500/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | DHFR 171/4885TSHR 4089/4885SMN1; SMN2 4306/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | DHFR 1274/4885TSHR 1187/4885SMN1; SMN2 1500/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | DHFR 642/4885TSHR 1226/4885SMN1; SMN2 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.